GPI
18.7.2022 09:02:06 CEST | Business Wire | Press release
The Global Phosphorus Institute (GPI) announced on June 16th 2022 the designation of Dr. Kaushik Majumdar as Interim Executive Director, with missions of operationalization of current Projects & Activities and further development of GPI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005057/en/
“We are pleased to welcome Kaushik at GPI to direct and develop further this global initiative,” said Hicham El Habti, the President of Mohammed VI Polytechnic University, Morocco (UM6P) and President of the GPI. “Having followed the developments made by Kaushik in the frame of other initiatives, I am convinced that with his extensive experience, he will highly contribute to move GPI forward significantly”.
As a recognized leader in agricultural development, Dr. Kaushik Majumdar brings over two decades of experience in building sustainable agricultural systems through his focus on crop nutrition research, extension and capacity building. Most recently in 2019, Dr. Majumdar led the establishment of African Plant Nutrition Institute (APNI) as its Director General, a position he will continue to hold. Before APNI, Dr. Majumdar was the Vice President of Asia and Africa Programs with the International Plant Nutrition Institute, where he coordinated plant nutrition research and outreach activities in China, Southeast Asia, South Asia, and Africa. Dr. Majumdar’s work in Africa and Asia has fostered effective teams, partnering and resource mobilization for improved sustainability within the most vulnerable of food production systems in the world. Dr. Majumdar is also an active influencer of policy through his contributions to the scientific literature and speaking forums.
“I look forward to leading GPI’s vision to engage stakeholders in the discussion about phosphorus stewardship and its role in addressing some of the most critical issues related to food systems resilience, global nutrition and environmental sustainability,” said Dr. Majumdar.
This appointment follows the resignation of the former Executive Director, Dr.Amit Roy.
Dr. Amit Roy decided to resign, with effective date 16th June 2022, to devote his time to activities related to Food and Fertilizer Securities, particularly in Less Developed Countries.
About GPI
The Global Phosphorus Institute (GPI) is a global organization with a holistic vision, footprint and participation to ensure responsible use of phosphorus through cutting-edge science and stakeholder dialogue.
It was launched on June 2nd, 2021 by Mohammed VI Polytechnic University (UM6P) and Ibn Rochd Foundation for Science and Innovation (FIRSI) both based in Morocco.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
Interactive Brokers Offers Eligible Clients Access to the Anthropic, PBC Initial Public Offering13.11.2026 11:00:00 CET | Press release
ADVERTISEMENT This advertisement constitutes an advertisement within the meaning of the Prospectus Regulation and marketing communication within the meaning of MiFID II and is prepared by and in the sole responsibility of Interactive Brokers Ireland Limited, North Dock One, 91/92 North Wall Quay, Dublin 1, D01 H7V7, Ireland, a firm authorized and regulated by the Central Bank of Ireland. Eligible clients of Interactive Brokers Ireland Limited can participate in the offering. Interactive Brokers Ireland Limited, part of Interactive Brokers Group (Nasdaq: IBKR), an automated global broker, today announced that eligible clients can participate in the initial public offering (the “Offering”) of Anthropic, PBC (the “Company”). Through the IBKR platform, eligible clients resident and located in Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Spain, and Sweden can review the Offering and submit an application during the offer period, which is open for all eligible clients
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
